Wedbush Lowers PT on Meridian Bioscience to $16

Symbols: VIVO
Share

Wedbush Securities has lowered the price target on Meridian Bioscience (NASDAQ: VIVO) from $22 to $16 and maintains its Neutral rating.


 
 
< Previous
Groupon: One Day Later
Next >
Bank of America Lowers PO On EnerNOC to $12
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust